Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD.
Hammond D, et al. Among authors: konopleva my.
Blood Cancer J. 2023 Sep 21;13(1):148. doi: 10.1038/s41408-023-00915-6.
Blood Cancer J. 2023.
PMID: 37735426
Free PMC article.
No abstract available.